-
Roth Capital Starts Verastem (VSTM) at Buy
-
Roth Capital Downgrades Verastem (VSTM) to Neutral
-
Verastem (VSTM) Sell-Off 'Ignores Main Value Driver', Roth Capital Says
-
Roth Capital Trims Verastem (VSTM) PT to $23 Followng Financing Activity
-
Roth Capital Affirms Verastem (VSTM) at 'Buy'; VS-6063, VS-5584 Combo Study Initiated
-
Verastem's (VSTM) Progress in COMMAND, Other Clinical Programs is 'Impressive' - Roth Capital
-
Roth 'Encouraged' by Verastem's (VSTM) VS-6063 Effect on Biomarkers of CSCs
-
Roth Affirms Verastem (VSTM) at 'Buy'; Encouraged by VS-6063's Potential in Mesothelioma, Ovarian Cancer
-
Roth Keeps Verastem (VSTM) at Buy; Sees Positioned for 'Potentially Transformative Year'
-
Verastem (VSTM) Prices $51.9M Common Stock Offering
-
Roth Capital Starts Verastem (VSTM) at Buy

